BioRestorative Therapies filings document the regulatory record of a Nevada regenerative medicine company listed on the Nasdaq Capital Market under BRTX. Its disclosures cover BRTX-100 clinical development for chronic lumbar disc disease, the ThermoStem metabolic program, the BioCosmeceutical platform, operating results, risk factors, and the use of capital for research, development, commercialization and working capital.
Recent filings include Form 8-K reports for financial results, Regulation FD presentations, executive compensation actions and material agreements, as well as registration statements for common stock, pre-funded warrants and common stock warrants. Proxy materials describe stockholder voting matters, charter-related proposals, board governance and compensation disclosures.
BioRestorative Therapies, Inc. appointed Donald J. Currie as a Class I director effective immediately on October 7, 2026, filling the vacancy created by Katharyn Field’s resignation effective August 31, 2026. He will serve until the Company’s 2027 annual meeting and until his successor is elected and qualified, or his earlier death, resignation or removal.
The Board also appointed Currie to the Compensation Committee and the Nominating and Corporate Governance Committee, and determined that he is an independent director under Nasdaq listing rules. He will receive a CAD $2,000 monthly cash fee, payable monthly in arrears, and reimbursement for reasonable out-of-pocket expenses; he will not participate in the standard non-employee director compensation program. The Company expects to enter into an indemnification agreement with him.
BioRestorative Therapies, Inc. (BRTX) reported that on September 4, 2026, Vice President of Research and Development Mr. Silva resigned from his employment and all officer positions, effective immediately. His notice states that the resignation is for “Good Reason” under an Executive Employment Agreement he asserts was entered into and later amended, tied to an alleged “Change in Control” following Board changes associated with a Revolving Loan Agreement with Bowery Group LLC. Mr. Silva is asserting entitlement to approximately $1.29 million in cash severance, acceleration of equity awards and continued benefits if the agreement is deemed valid and his resignation qualifies as “Good Reason.” The Board has acknowledged the resignation for record-keeping purposes but expressly disputes the validity and effect of the Employment Agreement and the characterizations in the notice, and the Company has reserved all rights, claims and defenses. The Board previously authorized an investigation by special counsel into the negotiation, approval, execution and amendment of this and similar executive employment agreements and has determined that, pending completion of that investigation and further Board action, no payments or benefits will be made under the Employment Agreement other than accrued base salary and amounts required by wage-payment law.
BioRestorative Therapies, Inc. (BRTX) filed an amended current report describing a change in independent auditors and an ongoing review related to its suspended biocosmeceutical product lines. On August 28, 2026, the company dismissed CBIZ CPAs P.C. as its independent registered public accounting firm, a decision approved by the Board on August 26, 2026 and ratified by the Audit Committee on September 1, 2026. CBIZ’s report on the fiscal year ended December 31, 2025 contained an explanatory paragraph expressing substantial doubt about the company’s ability to continue as a going concern, but no adverse or disclaimed opinion and no scope or accounting qualification.
CBIZ informed the company that a “reportable event” may exist because the previously disclosed suspension of ExoCR and BioX product lines and related reviews could, if further investigated, potentially affect the reliability of previously issued financial statements, though CBIZ has not identified any such impact or advised that prior statements should not be relied upon. Effective August 28, 2026, BioRestorative engaged Bush & Associates CPA as its new independent registered public accounting firm for 2026 and to perform new audits of 2025 and 2024. The Audit Committee has also hired an independent investigator; to date no previously unreported material information has been uncovered, and the investigation and business and regulatory reviews remain ongoing.
BioRestorative Therapies, Inc. (BRTX) is implementing a 1-for-20 reverse stock split of its common stock, effective at 4:30 p.m. Eastern Time on September 7, 2026. Every 20 shares outstanding immediately before the effective time will be automatically combined and reclassified into 1 share, with no change to par value.
Shares outstanding will be reduced from 27,622,556 to approximately 1,381,128, and authorized common shares will decrease proportionately from 1,500,000,000 to 75,000,000; authorized preferred shares remain at 20,000,000. Fractional positions will be rounded up so each affected holder receives one whole share, and percentage ownership will be unchanged aside from de minimis fractional adjustments.
The common stock will begin trading on a reverse split–adjusted basis on the Nasdaq Capital Market on September 8, 2026 under the symbol BRTX and a new CUSIP. The company states it is effecting the reverse split with the intention of regaining compliance with Nasdaq’s $1.00 minimum bid price continued listing requirement.
BioRestorative Therapies, Inc. (BRTX) reports a change in auditor and several leadership transitions. The company dismissed CBIZ CPAs P.C. as independent registered public accounting firm effective August 28, 2026, after CBIZ’s report on the year ended December 31, 2025 included an explanatory paragraph expressing substantial doubt about the company’s ability to continue as a going concern, though there were no disagreements or reportable events. Bush & Associates CPA was engaged as the new auditor for the 2026 fiscal year.
The board accepted the transition of Katharyn Field from Interim CEO, CFO, Treasurer and Secretary and her resignation as a director, and appointed director Mika Grasso as Interim CEO effective August 26, 2026 and Anna Skowron as non-employee, fractional Chief Financial Officer and Treasurer effective August 27, 2026. Both Mr. Grasso and Ms. Skowron will serve under consulting agreements, with monthly fees and eligibility for incentive and equity-based compensation. The board also reconstituted its committees and approved indemnification agreements for Grasso, Skowron and Field.
BioRestorative Therapies, Inc. (BRTX) reports receiving a delinquency notification letter from Nasdaq on August 21, 2026 because it did not timely file its Form 10‑Q for the quarter ended June 30, 2026, putting it out of compliance with Nasdaq Listing Rule 5250(c)(1). The company’s common stock continues to trade on the Nasdaq Capital Market under the symbol BRTX, and the notice has no immediate effect on the listing. BioRestorative Therapies has until October 20, 2026 to submit a plan to regain compliance; if Nasdaq accepts the plan, it may grant an exception of up to 180 days from the Form 10‑Q due date, through February 16, 2027. If Nasdaq does not accept the plan, the company may appeal to a Nasdaq Hearings Panel. The company states it is working to complete and file the Form 10‑Q and to submit a compliance plan.
BioRestorative Therapies, Inc. filed a notification of late filing for its Form 10-Q for the period ended June 30, 2026. The delay arises after the July 2026 resignations of the President/CEO/Chairman and CFO, who claimed “good reason” resignations under purported employment agreements that the company disputes. The CEO is serving concurrently as interim CFO, reducing financial reporting capacity and slowing preparation and review of the interim financial statements. Management, the accountants and the independent registered public accounting firm also need more time to evaluate the accounting treatment of the purported employment agreements and related claims. The company expects to file the Quarterly Report within five calendar days of the prescribed due date and indicates it will continue to report a net loss, needs additional capital, and has previously disclosed substantial doubt about its ability to continue as a going concern.
BioRestorative Therapies, Inc. reported that on August 7, 2026 it suspended, effective immediately, all orders and shipments of its biocosmeceutical product lines, including its ExoCR and BioX products, pending a business review and regulatory assessment. The company stated it has not decided to discontinue these product lines and is reviewing documentation, sourcing, and the regulatory status associated with them. The company noted that outcomes of this review, its ability to resume sales, related costs, and its capital needs are subject to significant risks and uncertainties described in its prior SEC reports.
Alta Partners LLC reports beneficial ownership of BioRestorative Therapies, Inc. common stock on an amended Schedule 13G. Alta Partners, a New York limited liability company, beneficially owns 1,338,133 shares of common stock, representing 4.99% of the class after applying a 4.99% beneficial ownership limitation contained in an applicable warrant.
Alta Partners has sole voting and dispositive power over all 1,338,133 shares and no shared voting or dispositive power. The filing is signed by Steven Cohen as Managing Member of Alta Partners LLC.
BioRestorative Therapies, Inc. has reported an initial statement of beneficial ownership for Esha Randhawa, who is identified as a director of the company. The report shows no reported transactions, no share purchases or sales, and no listed derivative positions for Randhawa.